Kura Oncology Files 8-K: Corporate Info Update, Nasdaq Listing Confirmed

Ticker: KURA · Form: 8-K · Filed: Jan 30, 2024 · CIK: 1422143

Kura Oncology, INC. 8-K Filing Summary
FieldDetail
CompanyKura Oncology, INC. (KURA)
Form Type8-K
Filed DateJan 30, 2024
Risk Levellow
Pages5
Reading Time6 min
Key Dollar Amounts$0.0001, $424 million, $146 million
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: corporate-update, regulatory-filing, administrative

TL;DR

**Kura Oncology filed an administrative 8-K, confirming corporate details and Nasdaq listing.**

AI Summary

Kura Oncology, Inc. filed an 8-K on January 30, 2024, to update its corporate information, including its address at 12730 High Bluff Drive, Suite 400, San Diego, CA 92130, and confirm its common stock is traded on The Nasdaq Global Select Market under the symbol KURA. This filing is largely administrative, indicating no major operational or financial shifts. For investors, this means the company is maintaining its regulatory compliance and there are no immediate red flags regarding its corporate structure or listing status.

Why It Matters

This filing confirms Kura Oncology's current corporate details and its listing on The Nasdaq Global Select Market, providing transparency and reassuring investors about its ongoing regulatory compliance.

Risk Assessment

Risk Level: low — This 8-K is primarily an administrative update and does not contain information that would significantly alter the company's risk profile.

Analyst Insight

A smart investor would note this filing as routine compliance, confirming basic corporate details without signaling any immediate need for action regarding their investment in Kura Oncology.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

What is the primary purpose of Kura Oncology, Inc.'s 8-K filing dated January 30, 2024?

The primary purpose of Kura Oncology, Inc.'s 8-K filing dated January 30, 2024, is to report current events, specifically updating corporate information under Item 5.02 and confirming its listing on The Nasdaq Global Select Market.

What is Kura Oncology, Inc.'s current business address as stated in the filing?

As stated in the filing, Kura Oncology, Inc.'s current business address is 12730 High Bluff Drive, Suite 400, San Diego, CA 92130.

On which exchange is Kura Oncology, Inc.'s common stock registered for trading?

Kura Oncology, Inc.'s common stock, with a par value of $0.0001 per share, is registered for trading on The Nasdaq Global Select Market under the trading symbol KURA.

What is the earliest event reported date in this 8-K filing?

The earliest event reported date in this 8-K filing is January 30, 2024.

Does this 8-K filing indicate any change in Kura Oncology, Inc.'s former name or address since its last report?

The filing explicitly states 'N/A' for 'Former Name or Former Address, if Changed Since Last Report,' indicating no change in its former name or address since the last report.

Filing Stats: 1,485 words · 6 min read · ~5 pages · Grade level 15.4 · Accepted 2024-01-30 07:08:06

Key Financial Figures

Filing Documents

Forward-Looking Statements

Forward-Looking Statements Any forward-looking statements in this Current Report on Form 8-K are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that the Company may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, applications and other interactions with regulatory bodies, risks associated with reliance on third parties to successfully conduct clinical trials, risks associated with the Company's cash needs, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human th

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Presentation Materials of Kura Oncology, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KURA ONCOLOGY, INC. Date: January 30, 2024 By: /s/ Teresa Bair Teresa Bair Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing